312 related articles for article (PubMed ID: 16420257)
1. Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.
Motoya T; Thevanayagam LN; Blaschke TF; Au S; Stone JA; Jayewardene AL; Chi J; Aweeka FT
HIV Med; 2006 Mar; 7(2):122-8. PubMed ID: 16420257
[TBL] [Abstract][Full Text] [Related]
2. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting serum protein binding of cocaine in humans.
Parker RB; Williams CL; Laizure SC; Lima JJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):605-10. PubMed ID: 7473145
[TBL] [Abstract][Full Text] [Related]
4. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
Mazoit JX; Cao LS; Samii K
J Pharmacol Exp Ther; 1996 Jan; 276(1):109-15. PubMed ID: 8558418
[TBL] [Abstract][Full Text] [Related]
5. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.
Morse DS; Abernethy DR; Greenblatt DJ
Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of serum protein binding of felodipine.
Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
[TBL] [Abstract][Full Text] [Related]
7. Interaction between human serum albumin and alpha 1-acid glycoprotein in the binding of lidocaine to purified protein fractions and sera.
Krauss E; Polnaszek CF; Scheeler DA; Halsall HB; Eckfeldt JH; Holtzman JL
J Pharmacol Exp Ther; 1986 Dec; 239(3):754-9. PubMed ID: 3795040
[TBL] [Abstract][Full Text] [Related]
8. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma.
Sun DL; Huang SD; Wu PS; Li J; Ye YJ; Jiang HD
Chirality; 2010 Jun; 22(6):618-23. PubMed ID: 19927376
[TBL] [Abstract][Full Text] [Related]
10. Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
Zsila F; Visy J; Mády G; Fitos I
Bioorg Med Chem; 2008 Apr; 16(7):3759-72. PubMed ID: 18289858
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
12. Binding of anti-HIV drugs to human serum albumin.
Bocedi A; Notaril S; Narciso P; Bolli A; Fasano M; Ascenzi P
IUBMB Life; 2004 Oct; 56(10):609-14. PubMed ID: 15814459
[TBL] [Abstract][Full Text] [Related]
13. Benoxaprofen: plasma binding and binding interactions with some drugs and endogenous compounds.
Albengres E; Urien S; Kusmierek J; Tillement JP
Eur J Rheumatol Inflamm; 1982; 5(2):87-97. PubMed ID: 6806105
[TBL] [Abstract][Full Text] [Related]
14. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 2000; 45(5):417-22. PubMed ID: 10803926
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.
Verbesselt R; Van Wijngaerden E; de Hoon J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jan; 845(1):51-60. PubMed ID: 16997640
[TBL] [Abstract][Full Text] [Related]
16. Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots.
Barri T; Trtić-Petrović T; Karlsson M; Jönsson JA
J Pharm Biomed Anal; 2008 Sep; 48(1):49-56. PubMed ID: 18565712
[TBL] [Abstract][Full Text] [Related]
17. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.
Holladay JW; Dewey MJ; Michniak BB; Wiltshire H; Halberg DL; Weigl P; Liang Z; Halifax K; Lindup WE; Back DJ
Drug Metab Dispos; 2001 Mar; 29(3):299-303. PubMed ID: 11181499
[TBL] [Abstract][Full Text] [Related]
18. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Zhang KE; Wu E; Patick AK; Kerr B; Zorbas M; Lankford A; Kobayashi T; Maeda Y; Shetty B; Webber S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
[TBL] [Abstract][Full Text] [Related]
19. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.
Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
Br J Clin Pharmacol; 2007 Mar; 63(3):315-21. PubMed ID: 16981898
[TBL] [Abstract][Full Text] [Related]
20. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.
Plum A; Müller LK; Jansen JA
Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):139-43. PubMed ID: 10893694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
